J&J Returns To The U.S. Iud Market
EVER SINCE A.H. ROBINS' Dalkon Shield proved harmful to thousands of women, Johnson & Johnson has steered clear of the U.S. intrauterine device market--even as its IUD sales boomed overseas. On July 28, though, J&J quietly acquired GynoPharma, which has marketed the ParaGard copper IUD in the U.S. since 1988. GynoPharma CEO Roderick Mackenzie sees the deal as vindication. "People thought I was crazy when I put the IUD on the market," he says. Mackenzie plans to develop more women's products through a new outfit, Gynetics.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- The Two Words That Will Help Get an Airline Upgrade Over the Phone
- Apple Plans Upgrades to Popular AirPods Headphones
- U.S. Stocks Rebound, Dollar Stumbles With Yields: Markets Wrap
- Jeremy Grantham Wants His Kids to Get Into Emerging Markets
- Los Angeles Cracks Down on Out-of-Control Hollywood Party Houses